Relay Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Relay Therapeutics (RLAY).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

12Buy

1Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$22Upside to Avg. PT+23.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$28→$29
Aug 14, 2026	JP Morgan	Priyanka Grover	PT Raise	Overweight	$28→$31
Aug 10, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$21→$26
Aug 7, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$27→$30
Jul 21, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$22→$31
Jul 16, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$29
Jul 8, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$28
May 26, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$22→$26
May 26, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$25→$28
May 20, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$19→$21
May 20, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$21→$27
May 19, 2026	Raymond James	Dane Leone	PT Raise	Strong Buy	$23→$26
Apr 29, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$19→$25
Apr 28, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$13→$22
Apr 28, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$17→$19
Apr 28, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$17→$21
Apr 28, 2026	Oppenheimer	Matthew Biegler	PT Raise	Outperform	$14→$18
Apr 14, 2026	Jones Trading	Boris Peaker	Initiate	Hold	$18
Apr 8, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$17→$21
Mar 23, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$14→$19

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $27 to $30.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.

Benzinga Newsdesk

Relay Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Relay Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

PRO
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

PRO
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

PRO
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

PRO
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

PRO
Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

People Also Watch

People Also Watch

Relay Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Relay Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

PROJP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

PROCitizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

PROBarclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

PROGoldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

PROCanaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

PRO
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

PRO
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

PRO
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

PRO
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

PRO
Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29